Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide Phase 1 in Healthy Chinese Subjects
NCT03745885Phase 1Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of Supaglutide up to 29 days, Time to Maximum Plasma Concentration (Tmax) of Supaglutide up to 29 days and 2 more. Started Dec 2018; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03745885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745885.